The Atypical Commissioner Turns Out Well: Hamburg Receives Mostly Fond Farewell

Margaret Hamburg’s public health, as opposed to academic medicine, background was off-putting to some in pharma initially, but she’ll leave the agency in March with high drug approval numbers and significant praise for new initiatives such as the breakthrough therapy program.